RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 ALLY 2
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 14
SP 9
OP 10
DO 10.1177/1559897715593920
UL http://mdc.sagepub.com/content/15/14/9.abstract
AB Results of the ALLY 2 trial involving more than 200 patients co-infected with HIV/HCV shows the efficacy and safety of the combined 12-week use of daclatasvir and sofosbuvir, with sustained virologic response for 12 weeks of 97% after a 12-week treatment. The benefit for HCV infection does not compromise the ongoing antiretroviral therapy.